RBC Capital lowered the firm’s price target on Intra-Cellular (ITCI) to $108 from $112 and keeps an Outperform rating on the shares as part of a broader research note previewing Q4 and 2025 earnings ...

NanoSyrinx, a synthetic biology company developing Nanosyringes™ as a novel platform for targeted intracellular delivery of biologic therapeutics, today announced the appointment of Thomas J. Farrell ...

Intra-Cellular Therapies (NASDAQ:ITCI) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement. Analysts anticipate ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side analysts ...